What records are connected here?
- Evidence lanes
- 3
- Source years
- 19
- Drugs@FDA applications
- 15
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2Evidence: Large human trialsHeart and blood vessels
Also called Integrilin2
Eptifibatide is a synthetic cyclic peptide that stops platelets from clumping together. It was first approved in the United States as Integrilin.1,2 Its U.S. label covers acute coronary syndrome (unstable angina or a heart attack without ST elevation) and patients undergoing percutaneous coronary intervention (PCI).1 In the PURSUIT trial of 10,948 people, death or a new heart attack within 30 days occurred in 14.2% with eptifibatide and 15.7% with placebo. The label warns that it can cause serious bleeding.1
| What it is | A cyclic heptapeptide that reversibly blocks the platelet glycoprotein IIb/IIIa receptor, according to the label.1 |
|---|---|
| FDA status | FDA-approved. Drugs@FDA lists Integrilin with an original approval date of May 18, 1998. The cited label has no boxed warning.1,2 |
| Human evidence | Three randomized, placebo-controlled trials (PURSUIT, IMPACT II and ESPRIT) in people with acute coronary syndromes or undergoing PCI, described in the label.1 |
| Evidence strength | Large randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned |
Eptifibatide is a cyclic heptapeptide, a ring of six amino acids and one related residue closed by a disulfide bridge, made by chemical peptide synthesis, according to the label.1
Drugs@FDA lists the original application, Integrilin (NDA 020718), as discontinued; the label cited here is from another manufacturer.1,2
The label states that eptifibatide reversibly inhibits platelet aggregation by preventing fibrinogen, von Willebrand factor and other molecules from binding the GP IIb/IIIa receptor on platelets.1
The inhibition reverses after the infusion stops, which is thought to result from eptifibatide detaching from platelets, according to the label.1
PURSUIT was a double-blind, randomized, placebo-controlled trial at 726 centers in 27 countries in 10,948 people with unstable angina or non-ST-elevation heart attack, according to the label.1
Death or new heart attack within 30 days occurred in 672 of 4,722 people (14.2%) on eptifibatide compared with 745 of 4,739 (15.7%) on placebo, a statistically significant difference, according to the label.1
The label also describes IMPACT II, in 4,010 people undergoing PCI, and ESPRIT, in people receiving coronary stents.1
Evidence-strength label: Large randomized human trials. How this label is assigned
Yes. Drugs@FDA lists Integrilin, application NDA 020718, with an original approval date of May 18, 1998.2
The eptifibatide label cited here (DailyMed SPL version 13, published May 21, 2026) states that it is indicated to decrease death or new heart attack in acute coronary syndrome, and death, new heart attack or urgent intervention in patients undergoing PCI.1
The label has no boxed warning. It is contraindicated in people with recent abnormal bleeding, severe uncontrolled high blood pressure, recent major surgery or stroke, and its warnings state that it can cause serious bleeding.1
How its benefit compares in current practice: in PURSUIT, care followed each site’s usual standards, and most patients were managed without PCI during the infusion, according to the label.1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Eptifibatide: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Eptifibatide are a bounded selection, not every registration or paper about Eptifibatide. For the years before Eptifibatide was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Eptifibatide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Eptifibatide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as Integrilin and generics for acute coronary syndrome and PCI. Randomized, placebo-controlled trials described in the label, including PURSUIT in 10,948 people, found fewer deaths or new heart attacks with eptifibatide. The label warns that it can cause serious bleeding.↗↗
Status sources checked through November 15, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as Integrilin and generics for acute coronary syndrome and PCI. Randomized, placebo-controlled trials described in the label, including PURSUIT in 10,948 people, found fewer deaths or new heart attacks with eptifibatide. The label warns that it can cause serious bleeding.↗↗
The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date November 3, 2026
Thrombolysis Alone vs With Argatroban or Eptifibatide: A Prespecified Subgroup Analysis of the MOST Trial.↗Added to PeptideScanner November 15, 2026Literature metadata · added November 15, 2026
Thrombolysis Alone vs With Argatroban or Eptifibatide: A Prespecified Subgroup Analysis of the MOST Trial.↗Source date November 3, 2026Literature metadata · added November 15, 2026
Evaluation of the Rational use of Eptifibatide among Patients with Acute Coronary Syndrome Referred to Shahid Chamran Heart Hospital.↗Source date October 10, 2026Literature metadata · added November 15, 2026
The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial.↗Source date May 18, 2026PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
16 of 16 selected trial records include at least one phase value; 16 of 16 include a status value in the retained structured contract.
30 of 30 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT00061373 at 2026-11-15T21:59:29.646Z. Its registry update date was 2013-02-04, and PeptideScanner's reviewed identity mapping was eptifibatide.
PeptideScanner retained ClinicalTrials.gov record NCT00089895 at 2026-11-15T21:59:29.646Z. Its registry update date was 2024-05-17, and PeptideScanner's reviewed identity mapping was eptifibatide.
PeptideScanner retained ClinicalTrials.gov record NCT00111566 at 2026-11-15T21:59:29.646Z. Its registry update date was 2013-11-28, and PeptideScanner's reviewed identity mapping was eptifibatide.
30 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span December 17, 1997 to November 3, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 41071964 in Neurology as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study, Comparative Study, with publication-date metadata of 2025-10-10 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 42846822 in Journal of research in pharmacy practice as Journal Article, with publication-date metadata of 2026-02-24 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 18772447 in Stroke as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, with publication-date metadata of 2008-09-04 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 24534128 in Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association as Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2014-02-15 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 25892271 in Cardiovascular therapeutics as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2015-08 (month precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 41227129 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2025-10-31 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 35926348 in Thrombosis research as Journal Article, with publication-date metadata of 2022-07-25 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03735979 at 2026-11-15T21:59:29.646Z. Its registry update date was 2025-02-07, and PeptideScanner's reviewed identity mapping was eptifibatide.↗
Literature metadata
PubMed lists PMID 36237613 in Frontiers in neurology as Journal Article, with publication-date metadata of 2022-09-27 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 23973010 in Thrombosis research as Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, with publication-date metadata of 2013-08-08 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00089895 at 2026-11-15T21:59:29.646Z. Its registry update date was 2024-05-17, and PeptideScanner's reviewed identity mapping was eptifibatide.↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 213599 with status AP dated 2024-05-09, and names eptifibatide among the application record's active ingredients.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026